Clinical Trial Detail

NCT ID NCT03256344
Title A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications

triple-receptor negative breast cancer

colorectal cancer

Therapies

Atezolizumab + Talimogene laherparepvec

Age Groups: senior adult

No variant requirements are available.